Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Simon Gibbs,
The development of new drugs for pulmonary arterial hypertension (PAH) represents a particular challenge in a disease where the number of patients is few. The formula for success to get a new drug to licensing takes a good idea followed by testing in cell culture, proof of concept studies in at least two complimentary animal models, target verification in human tissue and clinical trials up to and including phase III, according to Professor Ardi Ghofrani from Giessen. Not all classes of drug have been efficacious in humans: serotonin antagonists and vasoactive intestinal polypeptide may have failed because they did not adhere to this formula for success. Professor Ralph Schermuly described how many new candidate agents are being investigated including growth factor inhibitors, micro RNAs, molecules which alter metabolism and anti-inflammatory agents which incorporate Spiegelmeyer technology. While imatanib (a tyrosine kinase inhibitor) may be an effective treatment for PAH, dasatinib causes pulmonary hypertension which is reversible after discontinuation. Current drugs for PAH reduce mortality probably by increasing cardiac output. Professor Nazzareno Galie stressed that failure of therapy in PAH can be minimized by implementing guidelines, treating early, treating to goal, implementing combination therapy and when appropriate lung transplantation. Professor Marc Humbert discussed PAH where pulmonary vascular resistance could be normalized. In particular HIV associated PAH retroviral drugs may contribute to treatment of PAH, immunosuppressive agents may be effective in SLE and mixed connective tissue disease and calcium channel blockers in vasoreactive idiopathic PAH. There are many lessons to learn from treatment successes and failures and it is clear that there are subgroups of PAH patients who require special management of their disease. The complexity of delivering best treatment is increasing.
From bench to practice: pulmonary arterial hypertension
© 2017 European Society of Cardiology. All rights reserved